BACKGROUND: The optimal treatment for locally advanced superior @entity5 is not clear. The authors report long-term results of a trial examining the safety and efficacy of surgery followed by concurrent chemoradiation therapy for this disease. METHODS: Thirty-two @entity1 with resectable or marginally resectable superior @entity5 at The University of Texas @entity601 Anderson @entity5 Center from 1994 to 2010 were enrolled in a prospective trial. Surgery involved segmentectomy or lobectomy with en bloc resection of the involved chest wall and complete nodal staging; @entity1161 ( @entity1161 ) began 14 to 42 days later to a dose of 60 grays (Gy) in 50 1.2-Gy fractions if surgical margins were negative or 64.8 Gy in 54 1.2-Gy fractions if margins were positive. Two cycles of @entity2879 (50 mg/m(2) ) and @entity900 (50 mg/m(2) ) were given during @entity1161 , and another 3 cycles were given after @entity1161 . Eleven @entity1 underwent prophylactic cranial irradiation (PCI). RESULTS: The protocol completion rate was 78%. Gross total resection was accomplished in all 32 @entity1 ; 28% underwent R1 resection. Operative mortality was 0%. The most common surgical complication was @entity86 (25%). At a median follow-up time of 53.4 months (range, 2-154 months), the 2-year, 5-year, and 10-year rates of locoregional control were 84%, 76%, and 76%; distant @entity3 -free survival, 52%, 48%, and 48%; disease-free survival, 49%, 45%, and 45%; and overall survival, 72%, 50%, and 45%, respectively. The brain was the most common site of distant failure (n = 5), but no @entity1 who received PCI experienced brain @entity3 . CONCLUSIONS: Surgery followed by @entity86 is safe and effective for the treatment of marginally resectable superior @entity5 .

A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['sulcus tumors', 'Cancer'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity601 :: ('MESH:D009436', 'Disease') :: ['MD'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative chemoradiation', 'postoperative pneumonia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity5 :: (MESH:D009369,Disease) :: ['sulcus tumors']
